June 18, 2014 / 7:30 am, CEST
Lanthio Pharma B.V., the biopharmaceutical company focused on discovering and developing lanthipeptides, announced today that Bart Wuurman has resigned as CEO. Heinz Schwer will become the interim CEO of Lanthio Pharma. Heinz joins Lanthio Pharma from MorphoSys where he was responsible for the MorphoSys Innovation Capital unit.
Wil Hazenberg, Chairman of Lanthio Pharma’s Supervisory Board commented: “We are very grateful for the contribution Bart Wuurman has made to Lanthio Pharma as CEO. He has grown Lanthio from a university spin-out to a well funded biotech company with an Alliance with MorphoSys and a lead product ready for clinical development.
We are pleased that Heinz Schwer steps in as interim CEO of Lanthio Pharma. Before joining MorphoSys, Heinz was CEO and founder of Sloning BioTechnology, which was acquired by MorphoSys.”